DK2955195T3 - Antisemaphorin-3a-antistof og behandling af alzheimers sygdom og inflammatoriske immunsygdomme ved anvendelse af samme - Google Patents
Antisemaphorin-3a-antistof og behandling af alzheimers sygdom og inflammatoriske immunsygdomme ved anvendelse af samme Download PDFInfo
- Publication number
- DK2955195T3 DK2955195T3 DK14749177.3T DK14749177T DK2955195T3 DK 2955195 T3 DK2955195 T3 DK 2955195T3 DK 14749177 T DK14749177 T DK 14749177T DK 2955195 T3 DK2955195 T3 DK 2955195T3
- Authority
- DK
- Denmark
- Prior art keywords
- antisemaphorin
- alzheimer
- antibody
- disease
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013021309 | 2013-02-06 | ||
| PCT/JP2014/052758 WO2014123186A1 (ja) | 2013-02-06 | 2014-02-06 | 抗セマフォリン3a抗体、並びにこれを用いたアルツハイマー病及び免疫・炎症性疾患の治療 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2955195T3 true DK2955195T3 (da) | 2019-05-06 |
Family
ID=51299777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14749177.3T DK2955195T3 (da) | 2013-02-06 | 2014-02-06 | Antisemaphorin-3a-antistof og behandling af alzheimers sygdom og inflammatoriske immunsygdomme ved anvendelse af samme |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9879075B2 (da) |
| EP (1) | EP2955195B1 (da) |
| JP (1) | JP6372040B2 (da) |
| DK (1) | DK2955195T3 (da) |
| ES (1) | ES2728854T3 (da) |
| WO (1) | WO2014123186A1 (da) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2497498A4 (en) * | 2009-11-05 | 2013-04-17 | Univ Osaka | THERAPEUTIC ACTIVE FOR AUTOIMMUNE DISEASES OR ALLERGIES AND METHOD FOR SCREENING AFTER THE THERAPEUTIC ACTIVE SUBSTANCE |
| US9822367B2 (en) | 2013-02-21 | 2017-11-21 | Rsem, Limited Partnership | Inhibition of SEMA3A in the prevention and treatment of ocular hyperpermeability |
| US10105413B2 (en) * | 2013-06-13 | 2018-10-23 | Medical Research & Development Fund for Health Services Bnai Zion Medical Center | Semaphorin 3A for treatment of systemic lupus erythematosus |
| JP6692816B2 (ja) | 2014-09-05 | 2020-05-13 | アールエスイーエム,リミティド パートナーシップ | 炎症を処置および予防するための組成物および方法 |
| AU2016270373A1 (en) | 2015-06-05 | 2018-01-04 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
| US10688178B2 (en) | 2015-06-30 | 2020-06-23 | Osaka University | AntiPlexin A1 agonist antibody |
| US10604572B2 (en) | 2015-10-27 | 2020-03-31 | Samsung Life Public Welfare Foundation | Antibody to human and mouse Sema3A and use thereof |
| KR101854529B1 (ko) * | 2015-10-27 | 2018-05-04 | (주) 팬젠 | 인간 및 마우스 Sema3A에 교차결합하는 항체 및 그의 용도 |
| WO2017074013A1 (ko) * | 2015-10-27 | 2017-05-04 | 사회복지법인 삼성생명공익재단 | 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도 |
| US10640777B2 (en) | 2015-10-27 | 2020-05-05 | Samsung Life Public Welfare Foundation | Antibody to human and mouse SEMA3A and use thereof |
| US10604571B2 (en) | 2015-10-27 | 2020-03-31 | Samsung Life Public Welfare Foundation | Antibody to human and mouse SEMA3A and use thereof |
| KR20190114963A (ko) * | 2016-12-02 | 2019-10-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 에볼라 바이러스에 대한 사용을 위한 dna 항체 작제물 |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| EP3581645B1 (en) | 2017-02-10 | 2021-09-01 | Chiome Bioscience Inc. | Method for promoting diversification of antibody variable region |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| MX2021013671A (es) | 2019-05-09 | 2021-12-10 | Boehringer Ingelheim Int | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares. |
| WO2020261281A1 (en) * | 2019-06-27 | 2020-12-30 | Ramot At Tel-Aviv University Ltd. | Semaphorin 3a antibodies and uses thereof |
| US12560598B2 (en) | 2020-03-11 | 2026-02-24 | Genesis Intelligence, Llc | Cartridge-based automated rapid test analyzer |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| CN116490208A (zh) * | 2020-08-06 | 2023-07-25 | 史坦利科西斯治疗有限责任公司 | Il-8抗体及其使用方法 |
| US20220127344A1 (en) | 2020-10-23 | 2022-04-28 | Boehringer Ingelheim International Gmbh | Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina |
| WO2022185742A1 (ja) * | 2021-03-01 | 2022-09-09 | 学校法人埼玉医科大学 | 播種性血管内凝固症候群の予防又は治療用組成物 |
| WO2022207554A1 (en) * | 2021-03-30 | 2022-10-06 | Bayer Aktiengesellschaft | Anti-sema3a antibodies and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1418834A4 (en) | 2001-07-20 | 2007-04-04 | Sinai School Medicine | METHOD FOR DIAGNOSIS AND TREATMENT OF ALZHEIMER DISEASE AND PARKINSON DISEASE |
| AU2005214382B2 (en) | 2004-02-19 | 2011-08-04 | Genentech, Inc. | CDR-repaired antibodies |
| EP2497498A4 (en) * | 2009-11-05 | 2013-04-17 | Univ Osaka | THERAPEUTIC ACTIVE FOR AUTOIMMUNE DISEASES OR ALLERGIES AND METHOD FOR SCREENING AFTER THE THERAPEUTIC ACTIVE SUBSTANCE |
| US8871205B2 (en) * | 2009-11-25 | 2014-10-28 | The University Of North Carolina At Chapel Hill | Methods and compositions for the treatment of immune disorders |
-
2014
- 2014-02-06 WO PCT/JP2014/052758 patent/WO2014123186A1/ja not_active Ceased
- 2014-02-06 ES ES14749177T patent/ES2728854T3/es active Active
- 2014-02-06 US US14/766,062 patent/US9879075B2/en active Active
- 2014-02-06 JP JP2014560799A patent/JP6372040B2/ja active Active
- 2014-02-06 DK DK14749177.3T patent/DK2955195T3/da active
- 2014-02-06 EP EP14749177.3A patent/EP2955195B1/en active Active
-
2017
- 2017-12-19 US US15/847,740 patent/US10836814B2/en active Active
-
2020
- 2020-10-07 US US17/065,246 patent/US20210095012A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2728854T3 (es) | 2019-10-29 |
| JP6372040B2 (ja) | 2018-08-15 |
| US20210095012A1 (en) | 2021-04-01 |
| WO2014123186A1 (ja) | 2014-08-14 |
| US20150368327A1 (en) | 2015-12-24 |
| US10836814B2 (en) | 2020-11-17 |
| JPWO2014123186A1 (ja) | 2017-02-02 |
| EP2955195A4 (en) | 2016-11-02 |
| EP2955195A1 (en) | 2015-12-16 |
| US20180208644A1 (en) | 2018-07-26 |
| EP2955195B1 (en) | 2019-03-27 |
| US9879075B2 (en) | 2018-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2955195T3 (da) | Antisemaphorin-3a-antistof og behandling af alzheimers sygdom og inflammatoriske immunsygdomme ved anvendelse af samme | |
| DK2994160T3 (da) | Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g | |
| DK3221349T3 (da) | Humaniserede tau-antistoffer i Alzheimers sygdom | |
| EP3556773A4 (en) | HUMAN ANTI-CD73 ANTIBODY | |
| DK3024497T3 (da) | Fremgangsmåder og præparater til behandling af hjernesygdomme | |
| IL257065A (en) | Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders | |
| IL256079A (en) | Humanized and affinity matured antibodies to fcrh5 and methods of use | |
| EP2965277A4 (en) | PREDICTION OF APPROVAL OF TRANSACTIONS | |
| IL249195A0 (en) | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy | |
| IL240509B (en) | Fluorescence imaging of inflammatory diseases | |
| HUE049569T2 (hu) | Immunrendszerrel kapcsolatos és gyulladásos megbetegedések kezelése | |
| EP2954065A4 (en) | PARTITIONING AND PROCESSING OF ANALYTES AND OTHER SPECIES | |
| DK2903967T6 (da) | Acylaminopyrimidinderivater til behandling af virusinfektioner og andre sygdomme | |
| EP2948149A4 (en) | BY TOXIC ALDEHYDIC DISEASES AND TREATMENT | |
| DK2919796T3 (da) | Brug af akkermansia til behandling af stofskiftesygdomme | |
| HRP20182069T1 (hr) | Farmaceutski pripravci za liječenje alzheimerove bolesti | |
| HUE054783T2 (hu) | Pridopidin Huntington-kór kezelésében | |
| EP3011515A4 (en) | LANGUAGE TRANSACTION PROCESSING | |
| CL2016001519A1 (es) | Anticuerpos anti-tau(ps422) humanizados y métodos de utilización | |
| DK3081568T3 (da) | Sammensætninger og fremgangsmåder til behandling af alzheimers sygdom | |
| HUE051632T2 (hu) | Betegségek kezelésére szolgáló készítmények és eljárások | |
| DK2968470T3 (da) | Modificeret müllersk inhiberende substans (mis)-proteiner og anvendelser deraf til behandlingen af sygdomme | |
| IL269158A (en) | Compositions and methods for treating inflammatory diseases | |
| DK2961378T3 (da) | Fremgangsmåder til behandlingen af mitochondrisk sygdom | |
| DK3347002T3 (da) | Behandling af alzheimers sygdom i en bestemt patientpopulation |